Market Research Blog

From 2022 to 2032, the faecal pancreatic elastase testing market size is expected to increase by 7.7% CAGR, surpassing US$ 14.4 Mn in 2022. The most recent analysis indicates that in 2021, faecal pancreatic elastase ELISA kits held a sizable market share of more than 99.0% worldwide.

Fecal pancreatic elastase testing demand is increasing globally due to rising prevalence of exocrine pancreatic insufficiency (EPI) globally. Furthermore, growing incidence of chronic pancreatitis is expected to drive the growth in the global fecal pancreatic elastase testing market over the forecast period.

A list of Key Players Covered in the Fecal Pancreatic Elastase Testing Market Are:

• Laboratory Corporation of America® Holdings
• DiaSorin
• ScheBo Biotech AG
• Immundiagnostik AG
• Invivo Healthcare
• DRG Instruments GMBH
• Verisana Laboratories
• BÜHLMANN Laboratories AG
• CerTest Biotec S.L.
• R-Biopharm AG
• American Laboratory Products Company, Ltd.
• Vitassay Healthcare, S.L.U.

Download Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14507

Chronic pancreatitis is a leading cause for EPI. According to the National Pancreases Foundation, every year around 10-12 people out of 100,000 are affected by chronic pancreatitis in industrialized countries.

With prevalence of chronic pancreatitis, the number of EPI cases is also increasing. Hence, to test or diagnose EPI in chronic pancreatitis, the demand for fecal pancreatic elastase testing industry is surging globally.

The demand in the market is also predicted to rise with rising number of diagnostic labs offering FE-1 testing. Traditionally, exocrine pancreatic insufficiency was measured using the fecal fat test.

The hospital laboratories and diagnostic laboratories have started using the determination of pancreatic elastase from the stool sample. In the last few years, there has been an increase in the number of diagnostic laboratories offering this test. Some of the diagnostic laboratories offering this test include Mayo Clinic Laboratories, Dr Lal PathLabs, and others.

Key Takeaways from Market Study

• By product, fecal pancreatic elastase ELISA kits are expected to hold over 99.0% market value share by the end of 2032 and are expected to display growth at 7.7% CAGR over the forecast period.
• By indication, chronic pancreatitis will register 7.1% CAGR with the market share value of 34.7% over the forecast period.
• By end-user, hospitals held the highest segment share in terms of the market share value of 37.2% in 2021.
• Europe is considered the leading region with a value share of 43.4% in 2021, owing to the presence of advanced testing laboratories in the region with advanced techniques and equipment.

Request for Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-14507

“With increasing prevalence of chronic pancreatitis, the fecal pancreatic elastase testing market is expected to witness an advancement over the forecast period,” says an analyst of Future Market Insights.

Market Competition

Key players are adopting strategies such as mergers and acquisition of companies to expand their global presence. Market players such as DiaSorin, BioCheck Inc., and CerTest Biotec S.L., are enhancing their presence to gain competitive edge.

• In August 2021, BioCheck Inc acquired the international segment of DRG Diagnostics, which improved its diagnostic segment.
• In July 2021, Luminex Corporation was acquired by DiaSorin. This acquisition by DiaSorin gives access to strengthen its existing offering while expanding the Group presence in the U.S.
• In August 2019, CerTest Biotec S.L. has expanded its solutions for the diagnosis of infectious diseases in Japan and Germany.

Want more insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2032. The global fecal pancreatic elastase testing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on fecal pancreatic elastase testing market segment based on product– (fecal pancreatic elastase ELISA kits and rapid fecal pancreatic elastase kits), by indication (chronic pancreatitis, type 1 diabetes, cystic fibrosis, and others) by the end-user (hospitals, diagnostics laboratories, and speciality clinics) across seven major regions.

Top Related Reports Healthcare Market Insights

https://justnock.com/read-blog/8665

https://vishalt.blogzag.com/58125797/continuous-glucose-monitoring-systems-market-industry-future-set-to-massive-growth-with-high-cagr-value-by-2032

https://vishal.bluxeblog.com/44620430/continuous-glucose-monitoring-systems-market-size-share-cagr-forecast-report-by-2032

https://vishalttt.diowebhost.com/68079779/continuous-glucose-monitoring-systems-market-size-share-industry-trends-analysis-report-to-2032

https://loop.joshwho.net/posts/27720265?utm_source=manual

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

According to Future Market Insights, the global pediatric clinical trials Market Size is projected to grow steadily at a 5.3% value CAGR, during the forecast period 2022-2032. Earlier in 2021, this market was projected to have a global market valuation worth US$ 15 Billion and is expected to reach a sum of US$ 26.47 Billion by 2032.

Due to unmet healthcare needs in the pediatric patient population, there is a considerable product pipeline in the clinical phase of development. In the foreseeable future, the market will benefit from a robust medication development pipeline. Furthermore, in 2021, there were over 1,300 industry-sponsored pediatric clinical studies underway spanning a wide range of therapeutic categories, including communicable diseases, genetic disorders, neurologic issues, and numerous types of cancer.

Increasing pediatric medicine awareness, outsourcing in-house clinical trials to CROs, and the Increasing Burden of Pediatric Diseases such as Diabetes are projected to drive market growth globally. By region, North America is observed to have a substantial proportion of the pediatric clinical trial market, and this trend is projected to continue during the projection period.

The United States has the region’s most lucrative market. The rising prevalence of disorders in the country’s pediatric population is strengthening research initiatives to produce particular medications and expanding the number of clinical trials. This, together with other factors, is driving demand for the worldwide pediatric clinical trials market.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15017

Prominent Growth Drivers Influencing Pediatric Clinical Trials Industry

Increased Incidence of Chronic Diseases to accelerate Market Growth

The growing demand for innovative vaccines and biological products to treat infectious illnesses such as measles, polio, mumps, TB, rubella, influenza, whooping cough, chickenpox, malaria, and staphylococcus pharyngitis is likely to fuel market expansion. According to the World Health Organization (WHO) 2021, over 85 percent of infants worldwide are vaccinated against 27 illnesses; yet, 19.4 million children are unvaccinated, resulting in the deaths of 2-3 million children per year. According to the Centers for Disease Control and Prevention (CDC) fact page, in 2021, over 471,000 children in the United States had active epilepsy, accounting for approximately 0.6 percent of children aged 0-17 years.

At the same time, diabetes is a major concern among children nowadays. According to the International Diabetes Federation’s (IDF) Diabetes Atlas 2021, around 464 million children globally had diabetes in 2021. One million of these people (children and adolescents under the age of 20) have type 1 diabetes.

Rising parental awareness of pediatric clinical trials for dangerous infections and chronic disorders, as well as a substantial number of CROs performing pediatric studies, are driving the market. Autism is one of the most frequent childhood disorders. According to the CDC, one in every 44 children in the United States will have autism by 2021. The increased prevalence of autism among children is expected to propel the market for autism clinical trials, promoting pediatric clinical market growth globally.

Get In Touch With Our Team For 20% Flat Discount @ https://www.futuremarketinsights.com/ask-question/REP-GB-15017

Competitive Landscape

Due to the sheer presence of a few important players in the market with very few additional participants, the industry studied is consolidated. Market participants’ primary strategies included trial initialization, acquisitions, and collaborations, among others.

• Pfizer began a Phase 2/3 research for PAXLOVID tablets, which are especially intended to treat COVID-19 in young patients, in March 2022. PAXLOVID reduced the risk of hospitalization or death from any cause by 89 percent (within three days of symptom start) and 88 percent (within five days of appearance of symptoms).
• Novartis announced intentions to begin SMART, a Phase 3b clinical research to assess the safety and efficacy of Zolgensma (onasemnogene abeparvovec) in young children with spinal muscular atrophy, in April 2021. SMART is a multicenter, Phase 3b, single-arm, open-label study designed to assess the safety, tolerability, and efficacy of a one-time IV infusion of Zolgensma in pediatric patients with symptomatic SMA who have bi-allelic genetic changes in the SMN1 gene and any copy number of the SMN2 gene and weigh between 8.5 kg and 21 kg. The study will enroll 24 patients and will monitor them for a 12-month period.

Key Segments Covered in the Pediatric Clinical Trials Market Report

Pediatric Clinical Trials Market by Phase Type:

• Phase I Pediatric Clinical Trials
• Phase II Pediatric Clinical Trials
• Phase III Pediatric Clinical Trials
• Phase IV Pediatric Clinical Trials

Pediatric Clinical Trials Market by Study Design:

• Treatment Studies of Pediatric Clinical Trials
• Observational Studies of Pediatric Clinical Trials

Pediatric Clinical Trials Market by Therapeutic Areas:

• Pediatric Clinical Trials for Infectious Diseases
• Pediatric Clinical Trials for Oncology
• Pediatric Clinical Trials for Autoimmune/Inflammatory Diseases
• Pediatric Clinical Trials for Respiratory Disorders
• Pediatric Clinical Trials for Mental Health Disorders
• Pediatric Clinical Trials for Other Therapeutic Areas

Request for Report Ask A Question @ https://www.futuremarketinsights.com/ask-question/REP-GB-15017

Top Related Reports Healthcare Market Insights

https://bookmarksmywebs.com/continuous-glucose-monitoring-systems-market-gross-margin-cost-and-revenue-forecasts-to-2032/

https://www.blogger.com/blog/post/edit/preview/5007744562153417624/4822121902912267135

https://healthandfitness901316.blogspot.com/2022/10/continuous-glucose-monitoring-systems.html

https://myjoye.com/blogs/773/3265/continuous-glucose-monitoring-systems-market-report-overview-w

https://cybudz.com/posts/571

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

The global Animal Model Market is estimated to be valued at US$ 1.7 Bn in 2022, and is projected to reach US$ 2.4 Bn by 2028, registering a healthy CAGR of 6.6% from 2022 to 2028.

According to a recently compiled study by Future Market Insights, the global Animal Model Market will reflect an impressive CAGR through the forecast period, 2017 to 2026. Revenues from the global market for animal model are poised to surpass US$ 2,200 Mn by 2026-end.

Leveraging Animal Models offers Better Understanding of Different Diseases

Animals and human beings share a common biological as well as physiological structure. Animals possess shorter life cycle, however they have high genotype resemblance. It is simple and easy to control the animal environment as compared to the human beings.

Key Takeaways from FMI’s Report on Global Animal Model Market

North America is expected to remain the largest and fastest expanding market for animal model, with revenues estimated to surpass US$ 800 Mn by 2026-end. Between animal model markets in Asia-Pacific and Europe, the former will account for relatively larger revenue share, whereas the latter will expand at a comparatively higher CAGR through 2026. Although the market in South Korea will account for the lowest market revenue share, revenues are projected to expand at a relatively higher CAGR than those from the markets in Latin America and Middle East & Africa (MEA) through 2026.

On the basis of species, revenues from rats and mice are projected to account for over two-fifth share of the market by 2026-end. Revenues from use of rats in animal models will expand at the highest CAGR in the market through 2026. In addition, revenues from use of cats and monkeys in animal models will rise at a nearly equal CAGR through 2026. Dogs and pigs are expected to remain the least lucrative species used in animal models during the forecast period.

Contract research organizations (CROs) and biotechnology companies are anticipated to remain the fast expanding end-users of animal models. Revenues from these two end-users are collectively forecast to surpass US$ 850 Mn by 2026-end. In terms of revenues, academic & research institutions and pharmaceutical companies will continue to be dominant end-users in the global animal model market.

Basic and applied research application of animal model will continue to register the fastest expansion through 2026. However, drug discovery/development will remain the most lucrative application of animal model.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-3141

Key companies actively contributing to growth of the global animal model market include Transposagen Biopharmaceuticals, Inc., Envigo CRS SA, Crown Bioscience, Inc., Eurofins Scientific SE, Genoway SA, Taconic Biosciences, Inc., Trans Genic Inc, The Jackson Laboratory, Horizon Discovery Group plc, and Charles River Laboratories International, Inc.

Key Segments of Animal Model Industry Research

Animal Model Market by Species:

• Rats
• Mice
• Guinea Pigs
• Rabbits
• Monkeys
• Dogs
• Pigs
• Cats
• Other Species

Animal Model Market by End User:

• Academic & Research Institutions
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations (CROs)
• Other End Users

Animal Model Market by Application:

• Basic and Applied Research
• Drug Discovery/Development

Animal Model Market by Region:

• North America Animal Model Market
• Latin America Animal Model Market
• Europe Animal Model Market
• East Asia Animal Model Market
• South Asia & Pacific Animal Model Market
• Middle East & Africa (MEA) Animal Model Market

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-3141

Table of Content

1. Global Economic Outlook
2. Global Animal Model Market – Executive Summary
3. Global Animal Model Market Overview

3.1. Introduction

3.1.1. Global Animal Model Market Taxonomy

3.1.2. Global Animal Model Market Definition

3.2. Global Animal Model Market Size (US$ Mn) and Forecast, 2013-2028

3.2.1. Global Animal Model Market Y-o-Y Growth

3.3. Global Animal Model Market Dynamics

3.4. Global Animal Model Market Attractiveness By Region

3.5. Supply Chain

3.6. Cost Structure

3.7. Types of Animal Models

3.8. Animal Models in Disease Research

3.9. Regulatory Scenario in Animal Model

3.10. Product Life Cycle

3.11. PESTL Analysis

3.12. Technology Roadmap of Animal Model

3.13. Designing an Animal Model for Clinical Research

3.14. Number of Animals Used for Research and Testing Worldwide

3.15. Number of Animal Used for Research in South Korea (2008 – 2016)

3.16. Research and Development (R&D) Investment Country – Wise

3.17. List of Distributors

3.18. Key Participants Market Presence (Intensity Map) By Region

Inquire Before Buying Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-3141

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

The positive air pressure devices market is expected to enjoy a valuation of US$ 2.5 Bn by the end of the year 2022, and further expand at a CAGR rate of 6.4% to reach a valuation of ~US$ 4.7 Bn by the year 2032.

Global Positive Air Pressure Devices Market: Dynamics Influencing Growth

Favourable reimbursement coverage, increasing per capita healthcare expenditure, increasing prevalence of sleep disorders, rising awareness regarding the ill effects of untreated sleep apnea, increase in geriatric population, increase in obstructive sleep apnea, and increasing number of lifestyle diseases such as diabetes and obesity are favourable for the growth of the global positive air pressure devices market. However, alternative treatments for sleep apnea, lack of public awareness especially in the developing economies and pricing pressure are responsible restricting the growth of the global positive air pressure devices market.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-5623

Global Positive Air Pressure Devices Market: Segmentation Snapshot

The global market for positive air pressure devices is segmented by product type, by application type, by end user and by region.

By product type, the continuous positive airway pressure devices (CPAP) segment is expected to be the largest, with an estimated market valuation of just under US$ 2.4 Bn by the end of the forecast period in 2027.

By application type, obstructive sleep apnea is the largest segment and is expected to reach a value of around US$ 2.2 Bn by the end of the year of assessment at a stellar growth rate during the forecast period. The respiratory failures segment is the fastest growing segment registering a CAGR of 7.4% and is anticipated to hold high potential in the coming years.

By end user, hospitals have shown higher use of positive air pressure devices and this segment is estimated to be valued at about US$ 1,135 Mn by 2017 end. Home care settings segment is projected to be the fastest growing segment and is poised to reflect a CAGR of 8.8% and is the second largest segment in terms of value during the assessment period.

Among the regions, the positive air pressure devices market in Asia Pacific excluding Japan (APEJ) is poised to grow at the fastest rate to reach a noteworthy CAGR of 10.6% during the forecast period. By the end of 2027, Western Europe is expected to be the largest regional market in terms of valuation followed by North America.

Global Positive Air Pressure Devices Market: Competitive Assessment

The research report on the global air pressure devices market includes profiles of key players involved in the positive air pressure devices market. Company details such as company overview, key personnel, strategies, key financials, SWOT analysis, key developments, product portfolio analysis and geographical spread are mentioned in the report. Major players like ResMed Inc., Koninklijke Philips N.V., APEX MEDICAL CORP., Drive DeVilbiss Healthcare LLC, Medtronic, Inc., Fisher & Paykel Healthcare Limited, BMC Medical Co., Ltd., Khayat Medical, Servona GmbH, Somnetics International, Inc., 3B Medical, Inc., and Human Design Medical are profiled in this study.

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/ask-question/rep-gb-5623

Market Segmentation

The global positive air pressure devices market research report covers all angles by including a robust segmentation of the entire market. This ensures no aspect is left behind and a more real picture of the market can be drawn.

By Product Type:

• Continuous Positive Airways Pressure Devices (CPAP)
• Bi-level Positive Airway Pressure (BiPAP)/Variable Positive Airway Pressure (VPAP)
• Automatic Positive Airway Pressure Devices (APAP)

By End User:

• Hospitals
• Clinics
•  Home Care Settings
•  Others

By Application Type:

• Obstructive Sleep Apnea
•  Respiratory Failures
•  Others

By Region:

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific excluding Japan (APEJ)
• Japan
• Middle East and Africa (MEA)

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-5623

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

The global insulin delivery pens market is expected to enjoy a valuation of US$ 22.4 Bn by the end of the year 2022, and further expand at a CAGR rate of 8.0% to reach a valuation of ~US$ 48.6 Bn by the year 2032. Insulin pens are used as an effective solution for diabetes management. With the current technological advancements, insulin now comes with different variants like reusable pens that can be used by just loading insulin cartridges available in packs. Disposable insulin pens contain a prefilled cartridge and the entire pen is disposed or thrown away providing convenient delivery of insulin. Smart insulin pens are the latest advancement in diabetes management.  These smart insulin pens are either Bluetooth enabled wireless devices allowing automatic data sharing or devices that require data sharing with a dedicated USB data cable. These pens also come with a feature incorporating a clinician configured bolus calculator with the ability to deliver multiple insulin doses every day safely and discreetly.

Global Insulin Delivery Pens Market: Dynamics

Several factors contribute to the growth of the global insulin delivery pens market. One major driver is the move towards value based compensation models for therapies from unit priced payment models that are more commonly used to self-administer treatment for chronic diseases like diabetes. The shift is prominently seen in regions such as U.S. and Europe. This shift, in turn, results in increased demand for technology driven insulin delivery systems with higher levels of accuracy and patient compliance in addition to providing patients with the necessary coaching and education. The demand for smart insulin pens has also increased globally as healthcare stakeholders seek to gather useful information from clinical trials and the real world environment. Also, diabetes being chronic and a very expensive disease, people look for options to reduce the expenses related to the regular check-ups of diabetes. Smart insulin pens help patients keep a check on their diabetes with all the necessary dosage data pertaining to the disease and its effective management.

Request Sample Report:

https://www.futuremarketinsights.com/reports/sample/rep-gb-5605

Global Insulin Delivery Pens Market: Segmental Highlights

The global insulin delivery pens market is segmented into various segments based on product type, indication, distribution channel and region. The report presents the analysis of every market segment along with the yearly growth rate, revenue share and pricing analysis. Some of the key segmental highlights from the report are as under:

Among the regional markets, North America is expected to emerge the dominating market in terms of revenue, with a market value of almost US$ 2,000 Mn in 2017 and an estimated market value reaching over US$ 5,500 Mn by the end of forecast period in 2027.

In the product type segmentation, the reusable insulin pens segment is anticipated to dominate the market in terms of revenue share. Within the reusable insulin pens segment, refillable insulin pens is projected to stay at a high market valuation throughout the forecast period, reaching an estimated US$ 9,183.0 Mn by 2027 end at a CAGR of 10.2%.

By indication, the market is categorised into Diabetes Type 1 and Diabetes Type 2, among which the Diabetes Type 2 segment leads the market with a market valuation expected to reach over US$ 12,300 Mn by the end of 2027, growing at a CAGR of 10.5% during the forecast period.

In the distribution channel category, the hospital pharmacy segment is expected to remain dominant, with a market value of over US$ 1,900 Mn in 2017. This segment is in close competition with the online sales segment, which is ahead of the hospital pharmacy segment in terms of CAGR, with a growth rate of 11.7% during the forecast period.

Inquire Before Buying This Research Report:

https://www.futuremarketinsights.com/ask-question/rep-gb-5605

Global Insulin Delivery Pens Market: Competitive Landscape

This research report includes a brief profile of some of the major players in the global insulin delivery pens market. These descriptive profiles provide information on the overall development of the companies along with their future strategies. Some of the companies featured in the report are Sanofi S.A., Companion Medical, Inc., Patients Pending Ltd, Diamesco Co., Ltd., DiabNext, Owen Mumford Ltd, and Emperra GmbH E-Health Technologies.

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs

The global pneumonia diagnostics market is expected to enjoy a valuation of US$ 521.1 Mn by the end of 2022, and further expand at a CAGR of 5.6% from 2022 to 2032, reaching a valuation of ~US$ 899.4 Mn by 2032. Rising prevalence of pneumonia along with growing need for early detection of this medical condition for initiating a proper treatment is a key factor driving demand for pneumonia diagnostics in the market.

The viral pneumonia- based segment is predicted to witness the highest CAGR in the pneumonia diagnostics market over the course of the decade. The viral pneumonia segment of the pneumonia diagnostics market should cross US$ 180 million by end 2027, making it well worth the while of major stakeholders. Viral-based pneumonia is thought to cause approx. 8% of all cases of community-acquired pneumonia in the cases where patients required hospitalization.

The World Health Organization estimates that pneumonia accounted for 16% of all deaths of children below the age of 5 years – more than 920,000 in 2015. The WHO states that the cost of pneumonia antibiotic treatment in the same year for child survival and newly born babies is roughly US$ 110 million annually. Therefore, there is a pressing need to analyse the pneumonia diagnostics market. In an upcoming report titled ‘Pneumonia Diagnostics Market: Global Industry Analysis 2012 – 2016 and Opportunity Assessment 2017 – 2027’, Future Market Insights has undertaken a comprehensive study of the pneumonia diagnostics market that is poised to be worth more than US$ 685 million in 2027.

Request Sample PDF Brochure:

https://www.futuremarketinsights.com/reports/sample/rep-gb-2970

Region – North America and Western Europe Vital in Pneumonia Diagnostics Market

North America has the maximum share in the pneumonia diagnostics market and is on track to retain this share for some time. The US, primarily due to its world-class healthcare infrastructure and a geriatric population susceptible to pneumonia, represents a larger opportunity than Canada in the North America pneumonia diagnostics market. In addition to this, there is high awareness about pneumonia and its debilitating effects on both infants and the elderly. The North America pneumonia diagnostics market is expected to just push past US$ 200 million by the end of the forecast period.

Western Europe follows North America in the pneumonia diagnostics market with Germany and the UK comprising the bulk of the regional market. The two behemoths represent more than 40% of the Western Europe pneumonia diagnostics market between themselves and companies are advised to focus their attention there. The Western Europe pneumonia diagnostics market is anticipated to record a robust CAGR of 6.2% from 2017 to 2027, making it a region too lucrative to ignore in the global pneumonia diagnostics market. The market attractiveness of Germany is much higher than that of the UK at 1.6.

Competition Dashboard in the Pneumonia Diagnostics Market

Prominent companies profiled in the pneumonia diagnostics market report include:

• Thermo Fisher Scientific
• Alere
• Quidel Corporation
• Becton Dickinson and Company
• Meridian Bioscience
• Qiagen N.V.
• bioMérieux SA
• Bio-Rad Laboratories Inc.
• Cardinal Health Inc.
• Beckman Coulter Inc.

Get In Touch With Our Team For 20% Flat Discount:

https://www.futuremarketinsights.com/ask-question/rep-gb-2970

Takeaways

Changing global demographics coupled with greater medical awareness increase the potential for companies in the pneumonia diagnostics market. Manufacturers are seeking to introduce rapid diagnostics to exploit untapped opportunities and producers of pneumonia diagnostics have expanded the value chain to forward integrate the market in emerging economies. A high return on investment could be realized by shifting manufacturing from traditional culture techniques to rapid diagnostics at the point of care.

Pneumonia Diagnostics Market Taxonomy

Product Type:

• Streptococcus-based
• Legionella-based
• Chlamydophila-based
• Viral Pneumonia-based
• Mycoplasma Pneumonia-based

Region:

• North America
• Western Europe
• Eastern Europe
• Latin America
• Asia Pacific Excluding Japan
• Japan
• Middle East & Africa

Ask for Customization:

https://www.futuremarketinsights.com/customization-available/rep-gb-2970

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

Enquiries: sales@futuremarketinsights.com

LinkedIn| Twitter| Blogs